Phenylpropanolamine: Effects on subjective and cardiovascular variables at recommended over-the-counter dose levels

I. Liebson, George Bigelow, Roland R Griffiths, F. R. Funderburk

Research output: Contribution to journalArticle

Abstract

Two controlled clinical studies evaluated the effects of phenylpropanolamine HCL (PPA) on measures of blood pressure, pulse, and subjective state (mood). One hundred fifty subjects participated in a parallel groups design that compared a 75-mg sustained release (SR) preparation with a 25-mg tid. dosing regimen and placebo. Fifty-nine of these subjects participated in an additional cross-over component that compared SR PPA 75 mg with placebo. Measures of blood pressure, pulse, and subjective drug effect were obtained nine times throughout the course of a 12-hour session. Data analysis revealed no clinically and few statistically significant effects due to drug treatment. As expected, most measures showed circadian changes on both the cardiovascular and mood variables, which were not related to drug treatment. No euphorogenic or 'amphetaminelike' effects were noted. Although further work is warranted regarding the effects of chronic or higher-than-normal doses of PPA, the current studies suggest that PPA, at currently recommended dose levels, is not associated with adverse effects on either cardiovascular or subjective functioning.

Original languageEnglish (US)
Pages (from-to)685-693
Number of pages9
JournalJournal of Clinical Pharmacology
Volume27
Issue number9
StatePublished - 1987

Fingerprint

Phenylpropanolamine
Placebos
Pharmaceutical Preparations
Delayed-Action Preparations
Blood Pressure
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Phenylpropanolamine : Effects on subjective and cardiovascular variables at recommended over-the-counter dose levels. / Liebson, I.; Bigelow, George; Griffiths, Roland R; Funderburk, F. R.

In: Journal of Clinical Pharmacology, Vol. 27, No. 9, 1987, p. 685-693.

Research output: Contribution to journalArticle

@article{71b21967f09349ffbf633ccac88d3bd3,
title = "Phenylpropanolamine: Effects on subjective and cardiovascular variables at recommended over-the-counter dose levels",
abstract = "Two controlled clinical studies evaluated the effects of phenylpropanolamine HCL (PPA) on measures of blood pressure, pulse, and subjective state (mood). One hundred fifty subjects participated in a parallel groups design that compared a 75-mg sustained release (SR) preparation with a 25-mg tid. dosing regimen and placebo. Fifty-nine of these subjects participated in an additional cross-over component that compared SR PPA 75 mg with placebo. Measures of blood pressure, pulse, and subjective drug effect were obtained nine times throughout the course of a 12-hour session. Data analysis revealed no clinically and few statistically significant effects due to drug treatment. As expected, most measures showed circadian changes on both the cardiovascular and mood variables, which were not related to drug treatment. No euphorogenic or 'amphetaminelike' effects were noted. Although further work is warranted regarding the effects of chronic or higher-than-normal doses of PPA, the current studies suggest that PPA, at currently recommended dose levels, is not associated with adverse effects on either cardiovascular or subjective functioning.",
author = "I. Liebson and George Bigelow and Griffiths, {Roland R} and Funderburk, {F. R.}",
year = "1987",
language = "English (US)",
volume = "27",
pages = "685--693",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Phenylpropanolamine

T2 - Effects on subjective and cardiovascular variables at recommended over-the-counter dose levels

AU - Liebson, I.

AU - Bigelow, George

AU - Griffiths, Roland R

AU - Funderburk, F. R.

PY - 1987

Y1 - 1987

N2 - Two controlled clinical studies evaluated the effects of phenylpropanolamine HCL (PPA) on measures of blood pressure, pulse, and subjective state (mood). One hundred fifty subjects participated in a parallel groups design that compared a 75-mg sustained release (SR) preparation with a 25-mg tid. dosing regimen and placebo. Fifty-nine of these subjects participated in an additional cross-over component that compared SR PPA 75 mg with placebo. Measures of blood pressure, pulse, and subjective drug effect were obtained nine times throughout the course of a 12-hour session. Data analysis revealed no clinically and few statistically significant effects due to drug treatment. As expected, most measures showed circadian changes on both the cardiovascular and mood variables, which were not related to drug treatment. No euphorogenic or 'amphetaminelike' effects were noted. Although further work is warranted regarding the effects of chronic or higher-than-normal doses of PPA, the current studies suggest that PPA, at currently recommended dose levels, is not associated with adverse effects on either cardiovascular or subjective functioning.

AB - Two controlled clinical studies evaluated the effects of phenylpropanolamine HCL (PPA) on measures of blood pressure, pulse, and subjective state (mood). One hundred fifty subjects participated in a parallel groups design that compared a 75-mg sustained release (SR) preparation with a 25-mg tid. dosing regimen and placebo. Fifty-nine of these subjects participated in an additional cross-over component that compared SR PPA 75 mg with placebo. Measures of blood pressure, pulse, and subjective drug effect were obtained nine times throughout the course of a 12-hour session. Data analysis revealed no clinically and few statistically significant effects due to drug treatment. As expected, most measures showed circadian changes on both the cardiovascular and mood variables, which were not related to drug treatment. No euphorogenic or 'amphetaminelike' effects were noted. Although further work is warranted regarding the effects of chronic or higher-than-normal doses of PPA, the current studies suggest that PPA, at currently recommended dose levels, is not associated with adverse effects on either cardiovascular or subjective functioning.

UR - http://www.scopus.com/inward/record.url?scp=0023589237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023589237&partnerID=8YFLogxK

M3 - Article

C2 - 3680599

AN - SCOPUS:0023589237

VL - 27

SP - 685

EP - 693

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 9

ER -